Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2011

View Archived Issues

Nicotinic acetylcholine alpha5 receptor may represent new target of smoking cessation therapies

FDA grants accelerated approval to Hologic's Makena to reduce risk of preterm delivery

Snapshots: Recent clinical trials of briakinumab in psoriasis

Apremilast reduces severity of psoriasis and improves quality of life

Galapagos receives IWT grant for antiviral drug discovery

Merck & Co. reviews operations of fourth quarter 2010

TEAM trial compares exemestane alone to sequential tamoxifen/exemestane therapy in breast cancer

Algenpantucel-L plus adjuvant therapy improves survival of patients with resected pancreatic cancer

Combination of 90Y-hPAM4 and gemcitabine shows promise in advanced pancreatic cancer

TC-5214 enters phase IIb trial in major depressive disorder

Depomed reports phase I data on DM-1992 in Parkinson's disease

Helix BioPharma clear to conduct phase I L-DOS-47 trial in U.S.

Progenics and Salix Pharma enter into license agreement for Relistor

Harbor BioSciences completes phase I/IIa Apoptone trial in prostate cancer

Cell culture model mimics breast ductal system for design of nanoparticle therapies and diagnostics

Optimer Pharma and Astellas enter agreement for antibiotic fidaxomicin

Phosphagenics enters agreement to develop TPM-delivered antipsoriasis drug

Pharmaxis' Bronchitol approved in Australia for cystic fibrosis

NMS describes in silico model to predict myelosuppressive activity of drugs

Third phase III Avastin trial in ovarian cancer meets primary endpoint

FDA approves labeling update to Reyataz for HIV-infected pregnant women

Ansaris earns milestone payment from Ono Pharma with identification of kinase-related agent

Lundbeck is granted rights to several Cephalon products in Canada and Latin America

GSK adds new safety information and restrictions on use to rosiglitazone-containing medicines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...